HC Wainwright Has Optimistic Outlook of BioNTech Q2 Earnings

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) - Stock analysts at HC Wainwright raised their Q2 2025 earnings per share (EPS) estimates for BioNTech in a report issued on Wednesday, June 25th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of $3.78 per share for the quarter, up from their prior forecast of $3.72. HC Wainwright currently has a "Buy" rating and a $138.00 price objective on the stock. The consensus estimate for BioNTech's current full-year earnings is ($3.88) per share.

A number of other research analysts have also commented on the company. Wall Street Zen upgraded BioNTech from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. JPMorgan Chase & Co. cut their target price on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a research note on Thursday, May 22nd. Canaccord Genuity Group reissued a "buy" rating and issued a $171.44 price target on shares of BioNTech in a report on Tuesday, March 11th. Truist Financial restated a "buy" rating and issued a $155.00 price target (up from $151.00) on shares of BioNTech in a research report on Tuesday, June 3rd. Finally, BMO Capital Markets upped their price objective on shares of BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a research report on Tuesday, March 11th. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $137.86.

BioNTech Stock Performance

NASDAQ:BNTX traded up $1.34 during mid-day trading on Thursday, hitting $106.14. 402,644 shares of the company's stock traded hands, compared to its average volume of 943,618. The firm has a market capitalization of $25.51 billion, a price-to-earnings ratio of -31.22 and a beta of 1.29. The firm has a 50 day moving average of $102.49 and a two-hundred day moving average of $107.40. The company has a current ratio of 10.18, a quick ratio of 10.02 and a debt-to-equity ratio of 0.01. BioNTech has a 12 month low of $76.53 and a 12 month high of $131.49.

Institutional Investors Weigh In On BioNTech

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC grew its holdings in shares of BioNTech by 22.2% in the 4th quarter. FMR LLC now owns 7,701,476 shares of the company's stock valued at $877,583,000 after buying an additional 1,401,547 shares during the period. Capital International Investors lifted its holdings in BioNTech by 38.6% during the fourth quarter. Capital International Investors now owns 1,415,566 shares of the company's stock worth $161,304,000 after acquiring an additional 394,434 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in BioNTech by 94.6% during the first quarter. BNP Paribas Financial Markets now owns 1,195,470 shares of the company's stock worth $108,859,000 after acquiring an additional 581,173 shares in the last quarter. Bank of New York Mellon Corp grew its stake in BioNTech by 18,892.9% in the first quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company's stock valued at $63,593,000 after acquiring an additional 694,691 shares during the period. Finally, Invesco Ltd. increased its holdings in shares of BioNTech by 643.7% in the first quarter. Invesco Ltd. now owns 645,142 shares of the company's stock worth $58,747,000 after acquiring an additional 558,389 shares in the last quarter. Institutional investors own 15.52% of the company's stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.